← Back to patent-cliff list
BHV-1100
Tier C — Watch / tradeBHV-1100
Biohaven Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CD38
Indications (approved)：Multiple myeloma
Regional status
US
Phase II
2020-11-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of BHV-1100?
Approved indications include: Multiple myeloma.
When does the BHV-1100 patent expire?
No public expiry year is available for BHV-1100 yet; this page updates once verified.
How do I get a quote for BHV-1100 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06